Navigation Links
Allied Healthcare Net Falls on Manufacturing Delays
Date:5/12/2008

ST. LOUIS, May 12 /PRNewswire-FirstCall/ -- Allied Healthcare Products, Inc. (Nasdaq: AHPI) reported today that its net income for the third quarter ending March 31 fell 64 percent, from about $278,000 last year, or 4 cents per share, to about $100,000 in the current quarter, or 1 cent per share.

Sales for the third quarter increased by about $240,000 compared to the third quarter of the prior year. However, higher material and labor costs this fiscal year eroded margins and profits for the quarter.

For the first three quarters of the 2008 fiscal year ending March 31, Allied net income fell about 75 percent, from about $772,000 last year, or 10 cents per share, to about $193,000, or 2 cents per share this year.

Customer orders for the first three quarters of fiscal 2008 remained essentially flat compared to the previous period. However, actual sales declined by about $784,000, or about 1.8 percent, primarily because manufacturing delays slowed Allied shipments of some customer orders.

Allied's manufacturing problems led to eroded profit margins and reduced net income. Higher material and labor costs also pressured margins and net income. Allied was able to achieve a modest price increase of 0.8 percent. But that price relief could not offset the combined effects of manufacturing delays and higher costs.

Planned cost reduction efforts began to show positive effects in the last quarter, said Earl Refsland, Allied president and chief executive officer. The company will lower costs by bringing production of some products in house, he said. New investment in equipment is planned to help resolve the manufacturing throughput problem and reduce the cost of machined components.

Allied Healthcare Products,
'/>"/>

SOURCE Allied Healthcare Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Allied Security Holdings LLC to Hold a Conference Call to Discuss Fiscal Year 2007 Results on Thursday, March 27, 2008 at 11:00 AM EDT
2. C.V. Starr & Company to Offer Management Liability Lines From Allied World Assurance Company
3. Allied Healthcares Net Suffers on Flat Sales, Performance Issues
4. Diana Hatsis of Chiltern Will Present at the Joint Commission on Allied Health Personnel in Ophthalmology (JCAHPO) 35th Annual Continuing Education Program Held in Conjunction With the American Academy of Ophthalmology (AAO) Annual Meeting
5. SIEMENS, AlliedBarton, Methodist Hospital, and Family Planning Council Win Human Resources Department of the Year Awards
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. 34 SEIU Healthcare Leaders Urge UHW-W Members to Join in Support of New Plan to Win Quality Healthcare for All, Build Strength of Healthcare Workers
8. Retiring Nurses See Healthcare Advocacy as Second Career - Healthcare Liaison Workshop June 7-8 Shows Them How to Make Transition
9. New Study Shows Lowering Co-payments Can Lead to Lower Total Healthcare Costs, Improved Overall Health
10. Cepheid Signs Group Purchasing Contract With Premier Healthcare Alliance, One of the Largest U.S. Group Purchasing Organizations
11. Watson to Present at the Bank of America 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...Michigan received $5 million from the National Ins...esource of high-quality experimental data sets of ...mputer-aided drug design to a new level. , The ...puter programs that can predict the effectiveness ...ciate professor in the U-M College of Pharmacy and...
(Date:10/10/2008)... Johns Hopkins University School,of Medicine is la...ptimizing Adjuvant Breast Cancer Strategies: From ...ent key research data on the latest advances in,br...ents in the treatment of breast cancer have,led to...ons that are,increasingly tailored to the specific...
(Date:10/10/2008)... The Mobile Massage Team, (http://www.mobilemassag...massage,services for corporate wellness programs, ... today that it is expanding its service area throu...lphia metropolitan region., "We are quite excited...ed, massage programs and services throughout both...
(Date:10/10/2008)...nationally recognized faculty will,present the ver...east,cancer in the multimedia course "Optimizing A...to Treatment Selection" during National Breast,Can...icing oncologists and other interested,health care...t care,advances. This accredited course offers con...
Breaking Medicine News(10 mins):Health News:U-M to house leading drug database 2Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Mobile Massage Team Announces Expansion of On-Site Seated Massage Services Throughout Eastern Pennsylvania and the Greater Philadelphia Region 2Health News:Nationally Recognized Faculty Presents Latest Advances in Care of Patients with Breast Cancer 2
...hinese children became sick and one death was repo... vaccine.// According to reports about 2,500 child...ered the Hepatitis A vaccine on the 16 and 17 of J... a six-year-old child suffered an unspecified infe...
... organized by women’s magazine, Grazia reported th.../ The survey results reported that an overwhelmin...ndergo cosmetic surgery. The result of the survey ...dy was conducted in 1,000 women in the average age...
...ational study was done involving 598 068 nuclear i... done to estimate the risk of cancer after adminis...nternational collaborative study to estimate the c...the nuclear industry to find out the risk of cance...
...ducted by scientists at Wageningen University, Net...n as Vitamin B6) can slow down the cognitive decli... B9 has been known to help in the brain developmen... a long time now. Due to this reason it is adminis...
Other Medicine News:Health News:Cancer risk among nuclear industry workers 2
(Date:10/8/2008)...ment in patients with pulmonary arterial hype...ve limited benefit for this debilitating, rap...e, -- Imatinib mesylate, available as Gleevec(R...inhibit protein associated with PAH, -- Novarti...e in PAH in 2009 EAST HANOVER, N.J., Oct. 8 ...
(Date:10/7/2008)...exas Cardiac Arrhythmia,Institute (TCAI) at St. Da...nly a few sites in the nation to participate in an...reat persistent atrial fibrillation. TCAI, an,inte...specializing in heart,rhythm disorders, is a partn...s Cardiovascular Consultants., "This is just anot...
(Date:10/7/2008)...-- CEL-SCI Corporation,(NYSE: CVM ) announced tod...reement (MTA) with the National Institutes of Heal...r. Francesco M. Marincola, M.D., to,investigate th...ironment,caused by CEL-SCI,s cancer drug Multikine...ease and Immunogentics Section, Department of Tran...
(Date:10/7/2008)...ligen Therapeutics Inc.,today announced that in vi...dates were presented at the XXII International Com...ighlighted the candidates, efficacy in,several ani...se highlighted presentations, as well as several i...l the deep expertise and expanding,knowledge base ...
Breaking Medicine Technology:Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 2CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4Finding the source 3A Cells that initiate a common infant tumor identified 21225 1Brain Stem Cells Reverse Myelin Deficiency in Mice 21223 1Brain Stem Cells Reverse Myelin Deficiency in Mice 21223 2Brain Stem Cells Reverse Myelin Deficiency in Mice 21223 3Impact of Rising Gas Food Prices Felt Globally 21221 1Impact of Rising Gas Food Prices Felt Globally 21221 2Pioneering Safe Medication Return Initiative Reviewed During Pharmaceutical Disposal Summit 21219 1Pioneering Safe Medication Return Initiative Reviewed During Pharmaceutical Disposal Summit 21219 2
... ONCONASE for,Treatment of Neuroblastoma, BLOOMFIE...Alfacell Corporation today announced that new data... is active against naive and,chemoresistant neurob...vivo data published in Cancer,Letters (2007; Vol. ...ween Alfacell and Martin Michaelis, M.D., Ph.D., a...
...p; CEO of the Lupus,Foundation of America, Inc., W...- The Lupus,Foundation of America, Inc. and more t...iting the preliminary findings of the Phase,III cl...nt for,lupus kidney disease being tested by Asprev...ments for lupus patients is,critical because many ...
Other Medicine Technology:In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 2In Vitro and In Vivo Data Show Alfacell's Onocanse is Active,Against Naive and Chemoresistant Neuroblastoma Cells 3Lupus Foundation of America Statement on Results for Clinical Study,of CellCept Released by Aspreva Pharmaceutical Company 2
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
...s is a national reference laboratory and a worldwi...velopment. ARUP offers an extensive test menu of h... and anatomic pathology. Owned by the University o...an half of the nation's university teaching hospit...
Medicine Products: